Astrazeneca Pharma India Ltd (ASTRAZEN)
₹6,364.50
Mkt cap
₹15,911 Cr
P/E ratio
91.70
P/B
18.24
Div yield
0.57%
ROE
23.30%
ROCE
29.30%
EPS (TTM)
₹69.41
Book value
₹349
52W range
5,640–9,850
Sector
Healthcare
Price history
Previous close
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products. [1]
NSE ASTRAZENBSE 506820
Health check
Cautious
ValuationExpensive
ProfitabilityStrong
GrowthModerate
TechnicalsBearish
52-week range
−35.38% from high₹6,365
₹5,640+12.85% from low₹9,850
Current
₹6,364.50
Prev close
₹6,299.00
Day
+1.04%
Price performance
1D
+0.21%
1W
+5.41%
1M
+0.93%
3M
−22.01%
6M
−24.57%
1Y
−32.13%
YTD
−26.01%
Financials
Revenue, profit & margin
P/E ratio
91.7×
ASTRAZEN is 167% above the sector median of 34.4×
ASTRAZEN91.7×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 295 | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 | 559 | 612 | 579 | 683 | |
| Expenses | 228 | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 | 567 | 518 | 634 | |
| Operating Profit | 67 | 53 | 15 | 49 | 38 | 53 | 77 | 86 | 81 | 75 | 45 | 61 | 49 | |
| OPM % | 23% | 17% | 4.9% | 13% | 10% | 13% | 17% | 18% | 15% | 13% | 7% | 11% | 7% | |
| Other Income | 8 | 25 | 10 | 9 | -49 | 8 | -26 | 10 | 11 | 1 | 7 | 5 | 9 | |
| Interest | 0 | 0 | 1 | -0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 | 3 | 4 | 6 | 5 | |
| Profit before tax | 71 | 73 | 20 | 54 | -15 | 51 | 42 | 78 | 75 | 73 | 47 | 58 | 51 | |
| Tax % | 25% | 29% | 23% | 27% | -22% | 25% | 27% | 26% | 25% | 26% | 30% | 23% | 25% | |
| Net Profit | 54 | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 | 54 | 33 | 45 | 38 | |
| EPS in Rs | 21.54 | 20.95 | 6.32 | 15.79 | -4.72 | 15.37 | 12.34 | 23.30 | 22.33 | 21.69 | 13.04 | 17.95 | 15.17 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
5 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.55% · closed higher next day 16 of last 59
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 9 Nov '23◦ | 8 Feb '24◦ | 28 May '24 | 8 Aug '24◦ | 14 Nov '24 | 11 Feb '25◦ | 30 May '25◦ | 14 Aug '25 | 7 Nov '25◦ | 11 Feb '26◦ | 26 May '26◦ | 11 Aug '26 |
| Earnings day | −5.29% | −12.90% | +0.47% | +1.24% | −4.99% | +0.68% | +17.12% | −1.21% | +0.06% | −2.69% | −3.51% | −1.77% |
| +1 day | −5.73% | −17.14% | −0.94% | −1.32% | −10.00% | −0.71% | +17.12% | −0.02% | +0.80% | −1.64% | −3.69% | −2.27% |
| +5 days | −5.27% | −16.24% | −12.33% | +0.04% | −9.42% | −6.51% | +26.15% | +0.20% | +0.69% | −1.82% | −5.00% | −5.50% |
| +15 days | −1.63% | −17.06% | −0.83% | +1.29% | −6.86% | +0.25% | +11.34% | +7.47% | −0.12% | −4.01% | −4.84% | −14.50% |
| +30 days | +13.25% | −22.64% | +4.98% | +1.89% | +2.48% | +15.57% | +15.21% | +5.64% | +0.63% | −14.36% | −9.43% | −17.11% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 36 Per Share | 36.00 | 31 Jul '26 | 31 Jul '26 |
Shareholding
as of Sep 202675.00%Promoter
Promoters75.00%
FIIs2.64%0.04
DIIs7.09%1.01
Public15.27%0.97
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Astrazeneca Phar | ₹6,364.50 | 91.72 | 15,911 | 0.57% | 38 | −32.04% | 683 | +29.73% | 29.26% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts16
Announcements5
Board Meeting Intimation for Meeting Of The Board Of The Company To Be Held On Thursday, November 5, 2026 30 Oct - Board meets November 5, 2026 to approve Q2 and half-year FY2026 unaudited financial results; trading window closed.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 27 Oct - Please find the enclosed intimation of the Company as per the captioned subject for your reference.Announcement under Regulation 30 (LODR)-Press Release / Media Release 16 Oct - AstraZeneca Pharma India inaugurated a new 25,600 sq ft Mumbai corporate office on October 16, 2026.Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 16 OctAnnouncement under Regulation 30 (LODR)-Credit Rating 16 Oct - NSE Sustainability Ratings assigned AstraZeneca Pharma India ESG rating of 73 for FY2025-26.